Grifols announces new agreement with Henry Schein to distribute normal saline solution in the U.S.

A distribution agreement has been reached between Henry Schein, a provider of health care solutions, and Grifols, a producer of plasma-derived medicines. Henry Schein will market and distribute Grifols' 500 mL Normal Saline solution (0.9% Sodium Chloride Injection, USP) in the U.S. market.

A distribution agreement has been reached between Henry Schein, a provider of health care solutions, and Grifols, a producer of plasma-derived medicines. Henry Schein will market and distribute Grifols' 500 mL Normal Saline solution (0.9% Sodium Chloride Injection, USP) in the U.S. market. The company currently manufactures this product in its industrial complex in Murcia, Spain, and received FDA approval to market this product in the United States in 2017. This agreement is expected to help spur the internationalization of Grifols' Hospital Division as the U.S. represents one of the key markets in the growth strategy of this business line. It also represents potential opportunities for future commercialization for other products manufactured in Grifols' Murcia and Barcelona facilities.